Pediatric lung diseases

Respiratory conditions remain among the most common causes of morbidity in children, encompassing a wide spectrum that includes asthma, cystic fibrosis, bronchopulmonary dysplasia, congenital malformations, and infectious diseases. Pediatric lung diseases present unique challenges because growing lungs respond differently to injury and treatment compared with adults. Advances in neonatal and pediatric critical care have dramatically improved survival in premature infants with underdeveloped lungs, while innovations in molecular biology have transformed the outlook for genetic conditions such as cystic fibrosis. Early diagnosis through newborn screening, advanced imaging, and genetic testing is essential to initiating timely interventions. Treatment strategies vary widely, from inhaled medications and physiotherapy to advanced modalities like non-invasive ventilation and lung transplantation in severe cases. Preventive measures, including vaccination, nutritional support, and reduction of environmental exposures, play equally vital roles in safeguarding lung health during critical developmental stages. The management of pediatric lung diseases increasingly emphasizes family-centered care, integrating education and psychosocial support for both children and caregivers. Collaborative networks of pediatric pulmonologists, physiotherapists, nutritionists, and psychologists ensure holistic care. Emerging therapies, such as CFTR modulators and gene-targeted treatments, signal a new era of precision medicine in children. As scientific knowledge grows, the focus is shifting toward not only treating disease but also fostering optimal lung development and lifelong respiratory health.